RE:RE:RE:RE:RE:RE:RE: AZN SEEKING M AND PROSPECTS WITH PATENT EXPIRY OF CRESTOR?Just a few clarifications on this topic. Jardiance targets a completely different enzyme (SGLT2, a kidney glucose transporter) than RVX-208 (bromodomain-2 selective BET inhibitor). Their only commonality is that they are both used in high CVD risk diabetic patients.
Either JK or Toniv mentioned some drug that you thought I mentioned that raised HDL and have proven MACE reduction. I didn't mention one. You might be confusing with Jardiance. But as far as I know Jardiance had no effect on HDL.
Any comparison of the 3-point MACE Jardiance clinical trial EMPA-REG OUTCOME and the ASSURE/SUSTAIN 5-point MACE post-hoc analysis must acknowledge that most of the events on the ASSURE/SUSTAIN 5-point MACE were not of the strct 3-point MACE variety. So you cannot directly compare relative or absolute risk reductions between EMPA_REG OUTCOME and ASSURE/SUSTAIN post-hoc because there were so few 3-point MACE events in the ASSURE/SUSTAIN trials. You can look at the 2016 Atherosclerosis paper and see for yourself.
BearDownAZ